Comparison of suppressor and cytotoxic activity of blood mononuclears during adaptive immunotherapy of cancer patients with lymphokine-activated killer cells with a low dose of recombinant interleukin-2

1991 ◽  
Vol 112 (5) ◽  
pp. 1628-1631
Author(s):  
I. F. Abronina ◽  
T. A. Kupriyanova ◽  
A. V. Bolvachova ◽  
S. N. Bykovskaya ◽  
O. M. Dronova ◽  
...  
1989 ◽  
Vol 30 (3) ◽  
pp. 145-150 ◽  
Author(s):  
Timothy J. Eberlein ◽  
Mary L. Rodrick ◽  
Anthony F. Massaro ◽  
Sung-Eun Jung ◽  
John A. Mannick ◽  
...  

1989 ◽  
Vol 17 (5-6) ◽  
pp. 455-458 ◽  
Author(s):  
Neal P. Christiansen ◽  
B. J. Kennedy ◽  
Augusto C. Ochoa ◽  
Keith M. Skubitz ◽  
Fritz H. Bach

1991 ◽  
Vol 11 (6) ◽  
pp. 489-492 ◽  
Author(s):  
Donald A. Feinfeld ◽  
Vivette D’Agati ◽  
Janice P. Dutcher ◽  
Steven B. Werfel ◽  
Robert I. Lynn ◽  
...  

1988 ◽  
Vol 74 (5) ◽  
pp. 523-530 ◽  
Author(s):  
Carlo Gambacorti-Passerini ◽  
Marina Radrizzani ◽  
Licia Rivoltini ◽  
Edoardo Marchesi ◽  
Fernando Ravagnani ◽  
...  

A new procedure for activation of peripheral blood lymphocytes (PBL) with recombinant interleukin 2 (rIL2) is described. PBL obtained by leukapheresis were subjected to NH4Cl (ACK) treatment to clear erythrocyte contamination; Ficoll separation was not performed. PBL were subsequently seeded in 10-floor multitrays (Cell Factory™, CF), gasified and incubated at 37 °C for 3-4 days in a humidified 5% CO2 atmosphere. This procedure achieved an activation (evaluated as cytotoxicity and proliferation) comparable with that obtained by culturing PBL in small flasks. Optimal activation of PBL was achieved in CF even in the presence of granulocyte contamination of up to 40%. It was also possible to freeze, thaw and recover most of the frozen cells and their cytotoxic activity. With this procedure therefore large quantities of lymphokine activated killer cells (LAK) can be easily produced to be used in adoptive immunotherapy trials.


Sign in / Sign up

Export Citation Format

Share Document